406 related articles for article (PubMed ID: 38167055)
1. Tumor immune microenvironment-based therapies in pancreatic ductal adenocarcinoma: time to update the concept.
Luo W; Wen T; Qu X
J Exp Clin Cancer Res; 2024 Jan; 43(1):8. PubMed ID: 38167055
[TBL] [Abstract][Full Text] [Related]
2. Crosstalk between Tumor and Stromal Cells in Pancreatic Ductal Adenocarcinoma.
Sperb N; Tsesmelis M; Wirth T
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32752017
[TBL] [Abstract][Full Text] [Related]
3. Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma.
Neuzillet C; Tijeras-Raballand A; Ragulan C; Cros J; Patil Y; Martinet M; Erkan M; Kleeff J; Wilson J; Apte M; Tosolini M; Wilson AS; Delvecchio FR; Bousquet C; Paradis V; Hammel P; Sadanandam A; Kocher HM
J Pathol; 2019 May; 248(1):51-65. PubMed ID: 30575030
[TBL] [Abstract][Full Text] [Related]
4. Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma: An Update on Heterogeneity and Therapeutic Targeting.
Vaish U; Jain T; Are AC; Dudeja V
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948209
[TBL] [Abstract][Full Text] [Related]
5. Stromal HIF2 Regulates Immune Suppression in the Pancreatic Cancer Microenvironment.
Garcia Garcia CJ; Huang Y; Fuentes NR; Turner MC; Monberg ME; Lin D; Nguyen ND; Fujimoto TN; Zhao J; Lee JJ; Bernard V; Yu M; Delahoussaye AM; Jimenez Sacarello I; Caggiano EG; Phan JL; Deorukhkar A; Molkentine JM; Saur D; Maitra A; Taniguchi CM
Gastroenterology; 2022 Jun; 162(7):2018-2031. PubMed ID: 35216965
[TBL] [Abstract][Full Text] [Related]
6. CAF Subpopulations: A New Reservoir of Stromal Targets in Pancreatic Cancer.
Pereira BA; Vennin C; Papanicolaou M; Chambers CR; Herrmann D; Morton JP; Cox TR; Timpson P
Trends Cancer; 2019 Nov; 5(11):724-741. PubMed ID: 31735290
[TBL] [Abstract][Full Text] [Related]
7. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.
Zhang YF; Jiang SH; Hu LP; Huang PQ; Wang X; Li J; Zhang XL; Nie HZ; Zhang ZG
Chin Clin Oncol; 2019 Apr; 8(2):18. PubMed ID: 31070038
[TBL] [Abstract][Full Text] [Related]
8. Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options.
Kabacaoglu D; Ciecielski KJ; Ruess DA; Algül H
Front Immunol; 2018; 9():1878. PubMed ID: 30158932
[TBL] [Abstract][Full Text] [Related]
9. Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions.
Lin W; Noel P; Borazanci EH; Lee J; Amini A; Han IW; Heo JS; Jameson GS; Fraser C; Steinbach M; Woo Y; Fong Y; Cridebring D; Von Hoff DD; Park JO; Han H
Genome Med; 2020 Sep; 12(1):80. PubMed ID: 32988401
[TBL] [Abstract][Full Text] [Related]
10. The critical roles of activated stellate cells-mediated paracrine signaling, metabolism and onco-immunology in pancreatic ductal adenocarcinoma.
Fu Y; Liu S; Zeng S; Shen H
Mol Cancer; 2018 Feb; 17(1):62. PubMed ID: 29458370
[TBL] [Abstract][Full Text] [Related]
11. The Tango between Cancer-Associated Fibroblasts (CAFs) and Immune Cells in Affecting Immunotherapy Efficacy in Pancreatic Cancer.
Stouten I; van Montfoort N; Hawinkels LJAC
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240052
[TBL] [Abstract][Full Text] [Related]
12. Apoptosis in the Pancreatic Cancer Tumor Microenvironment-The Double-Edged Sword of Cancer-Associated Fibroblasts.
Pfeifer E; Burchell JM; Dazzi F; Sarker D; Beatson R
Cells; 2021 Jul; 10(7):. PubMed ID: 34359823
[TBL] [Abstract][Full Text] [Related]
13. The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications.
Liu X; Xu J; Zhang B; Liu J; Liang C; Meng Q; Hua J; Yu X; Shi S
Mol Cancer; 2019 Dec; 18(1):184. PubMed ID: 31831007
[TBL] [Abstract][Full Text] [Related]
14. Cellular collusion: cracking the code of immunosuppression and chemo resistance in PDAC.
Musiu C; Lupo F; Agostini A; Lionetto G; Bevere M; Paiella S; Carbone C; Corbo V; Ugel S; De Sanctis F
Front Immunol; 2024; 15():1341079. PubMed ID: 38817612
[TBL] [Abstract][Full Text] [Related]
15. Combined MEK and STAT3 Inhibition Uncovers Stromal Plasticity by Enriching for Cancer-Associated Fibroblasts With Mesenchymal Stem Cell-Like Features to Overcome Immunotherapy Resistance in Pancreatic Cancer.
Datta J; Dai X; Bianchi A; De Castro Silva I; Mehra S; Garrido VT; Lamichhane P; Singh SP; Zhou Z; Dosch AR; Messaggio F; Ban Y; Umland O; Hosein PJ; Nagathihalli NS; Merchant NB
Gastroenterology; 2022 Dec; 163(6):1593-1612. PubMed ID: 35948109
[TBL] [Abstract][Full Text] [Related]
16. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma.
Fan JQ; Wang MF; Chen HL; Shang D; Das JK; Song J
Mol Cancer; 2020 Feb; 19(1):32. PubMed ID: 32061257
[TBL] [Abstract][Full Text] [Related]
17. Pancreatic ductal adenocarcinoma: tumor microenvironment and problems in the development of novel therapeutic strategies.
Kuznetsova A; Popova O; Panchenkov D; Dyuzheva T; Ivanov A
Clin Exp Med; 2023 Jul; 23(3):619-643. PubMed ID: 36085429
[TBL] [Abstract][Full Text] [Related]
18. Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma therapy: Challenges and opportunities.
Qin Q; Yu R; Eriksson JE; Tsai HI; Zhu H
Cancer Lett; 2024 Jun; 591():216859. PubMed ID: 38615928
[TBL] [Abstract][Full Text] [Related]
19. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
Front Immunol; 2021; 12():648917. PubMed ID: 33777046
[No Abstract] [Full Text] [Related]
20. Understanding Tricky Cellular and Molecular Interactions in Pancreatic Tumor Microenvironment: New Food for Thought.
Agostini A; Orlacchio A; Carbone C; Guerriero I
Front Immunol; 2022; 13():876291. PubMed ID: 35711414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
